Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Current Opinion in Lipidology|September 27, 2024
Oral agents for lowering lipoprotein(a)Stephen J Nicholls, Adam J Nelson, Laura F Michael
Mini Reviews in Medicinal Chemistry|August 17, 2005
The pharmacology of LXRLaura F Michael, Jeffrey M Schkeryantz, Thomas P Burris
Biochemical and Biophysical Research Communications|February 22, 2005
Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptorRajesh S Savkur, Kelli S Bramlett, Laura F Michael, et al.
Current Pharmaceutical Biotechnology|March 16, 2011
Opportunities for pharmacotherapy at the intersection of metabolic syndrome and hemostasisLaura F Michael, Veena Rao, Patrick McCollam, et al.
Journal of Molecular Graphics & Modelling|August 23, 2003
Molecular determinants of LXRalpha agonismMinmin Wang, Jeffrey Thomas, Thomas P Burris, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 27, 2004
Ligand-dependent coactivation of the human bile acid receptor FXR by the peroxisome proliferator-activated receptor gamma coactivator-1alphaRajesh S Savkur, Jeffrey S Thomas, Kelli S Bramlett, et al.
Molecular Genetics and Metabolism|October 7, 2004
T0901317 is a dual LXR/FXR agonistKeith A Houck, Kristen M Borchert, Christopher D Hepler, et al.
JAMA|November 18, 2024
Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical TrialStephen J Nicholls, Wei Ni, Grace M Rhodes, et al.
Endocrinology|November 27, 2004
Regulation of carbohydrate metabolism by the farnesoid X receptorKeith R Stayrook, Kelli S Bramlett, Rajesh S Savkur, et al.
ACS Chemical Biology|March 3, 2021
The Angiopoietin-Like Protein 3 and 8 Complex Interacts with Lipoprotein Lipase and Induces LPL CleavageNajia Jin, William F Matter, Laura F Michael, et al.
Pageof 3